Liver Transplantation
Volume 12, Issue 3 p. 494
Erratum
Free Access

Erratum

First published: 23 February 2006
https://doi.org/10.1002/lt.20726

In the January 2006 issue of Liver Transplantation, the following article:

Park, JM, Lake KD, Arenas JD, Fontana RJ. Efficacy and Safety of Low-Dose Valganciclovir in the Prevention of Cytomegalovirus Disease in Adult Liver Transplant Recipients. Liver Transpl 2006;12:112-116 should have a completed reference list as follows.
  • 1

    Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998;338:1741–1751.

  • 2

    Flechner SM, Avery RK, Fisher R, Mastroianni BA, Papajcik DA, O'Malley KJ, et al. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation 1998;66:1682–1688.

  • 3

    Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group. Lancet 1997;350:1729–1733.

  • 4

    Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF, et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transplant Infect Dis 2000;2:112–117.

  • 5

    Winston DJ, Busuttil RW. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Transplantation 2003;75:229–233.

  • 6

    Winston DJ, Busuttil RW. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors. Transplantation 2004;77:305–308.

  • 7

    Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995;346:69–74.

  • 8

    Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrobial Agents & Chemotherapy 2000;44:2811–2815.

  • 9

    Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus dis-ease in solid organ transplant recipients. Am J Transplant 2004;4:611–620.

  • 10

    Food and Drug Administration Web site. Available at: http://www.fda.gov/medwarch/SAFETY/2003/valcyte.htm. Accessed May 2, 2005.

  • 11

    Akalin E, Sehgal V, Ames S, Hossain S, Daly L, Barbara M, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003;3:731–735.

  • 12

    Gelone DK, Cibrik D, Vogler S, Leichtman AB, Lake KD. Comparative efficacy and safety of low-dose valganciclovir vs oral ganciclovir for the prevention of cytomegalovirus disease in renal allograft recipients [abstract]. Am J Transplant 2003;3[S5]:511.

  • 13

    Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis. Pharmacotherapy 20004;24:1323–1330.

  • 14

    Humar A, Paya C, Pescovitz MD, Domínguez E, Washburn K, Blumberd E et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am J Transplant 2004;4:644–649.

  • 15

    Akalin E, Bromberg JS, Sehgal V, Ames S, Murphy B. Decreased incidence of cytomegalovirus infection in thymoglobulin-treated transplant patients with 6 months of valganciclovir prophylaxis [letter]. Am J Transplant 2004;4:148–149.

  • 16

    Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000;356:645–649.

  • 17

    Bhorade SM, Lurain NS, Jordan A, Leischner J, Villanueva J, Durazo R, et al. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant 2002; 21:1274–1282.

  • 18

    Boivin G, Goyette N, Gilbert C, Roberts N, Macey K, Paya C,et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004;189:1615–1618.

    The full text of this article hosted at iucr.org is unavailable due to technical difficulties.